Healthequity (HQY) Cost of Revenue (2013 - 2026)

Healthequity has reported Cost of Revenue for 14 years, with the latest figure at -$198.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 155.98% year-over-year to -$198.6 million; the trailing twelve-month figure through Jan 2026 stood at $25.5 million (down 94.88% YoY), and the FY2026 full-year result was $95.2 million, down 77.46% from the prior year.
• Cost of Revenue for Q1 2026 stood at -$198.6 million, down from $24.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $354.9 million in Q1 2025, with the low at -$198.6 million in Q1 2026.
• Average Cost of Revenue over 5 years is $67.7 million, with a median of $88.8 million recorded in 2022.
• Year-over-year, Cost of Revenue surged 403.93% in 2024 and tumbled 155.98% in 2026.
• Tracing HQY's Cost of Revenue over 5 years: stood at $88.8 million in 2022, then tumbled by 77.86% to $19.7 million in 2023, then increased by 15.16% to $22.6 million in 2024, then gained by 7.84% to $24.4 million in 2025, then sank by 913.71% to -$198.6 million in 2026.
• The last three Cost of Revenue figures came in at -$198.6 million (Q1 2026), $24.4 million (Q4 2025), and $93.2 million (Q3 2025), per Business Quant data.

Peer Comparison